CINECA IRIS Institutional Research Information System

SIRAVEGNA, GIULIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.068
AS - Asia 4.928
EU - Europa 4.825
OC - Oceania 154
SA - Sud America 137
AF - Africa 57
Continente sconosciuto - Info sul continente non disponibili 13
Totale 17.182
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.867
CN - Cina 3.152
IT - Italia 1.445
DE - Germania 664
JP - Giappone 568
GB - Regno Unito 508
FR - Francia 365
ES - Italia 329
SE - Svezia 227
IN - India 226
IE - Irlanda 214
KR - Corea 195
CA - Canada 155
SG - Singapore 146
HK - Hong Kong 140
TW - Taiwan 138
NL - Olanda 124
AU - Australia 118
FI - Finlandia 111
BE - Belgio 101
CH - Svizzera 98
BR - Brasile 90
GR - Grecia 84
TR - Turchia 83
PL - Polonia 74
DK - Danimarca 69
UA - Ucraina 67
RU - Federazione Russa 64
VN - Vietnam 63
AT - Austria 44
RO - Romania 43
MX - Messico 42
NO - Norvegia 38
TH - Thailandia 38
NZ - Nuova Zelanda 36
PT - Portogallo 35
HU - Ungheria 29
IL - Israele 29
CZ - Repubblica Ceca 28
MY - Malesia 22
ID - Indonesia 20
EG - Egitto 17
IR - Iran 17
AR - Argentina 16
SA - Arabia Saudita 15
AM - Armenia 13
CL - Cile 12
CO - Colombia 11
ZA - Sudafrica 11
BA - Bosnia-Erzegovina 10
PK - Pakistan 10
LB - Libano 9
HR - Croazia 8
SI - Slovenia 8
SK - Slovacchia (Repubblica Slovacca) 7
AE - Emirati Arabi Uniti 6
BN - Brunei Darussalam 6
DZ - Algeria 6
EU - Europa 6
NG - Nigeria 6
BG - Bulgaria 5
IS - Islanda 5
JO - Giordania 5
LU - Lussemburgo 5
PH - Filippine 5
RS - Serbia 5
AP - ???statistics.table.value.countryCode.AP??? 4
EC - Ecuador 4
EE - Estonia 4
KE - Kenya 4
MA - Marocco 4
OM - Oman 4
GE - Georgia 3
KZ - Kazakistan 3
MO - Macao, regione amministrativa speciale della Cina 3
MT - Malta 3
SN - Senegal 3
A1 - Anonimo 2
ET - Etiopia 2
IM - Isola di Man 2
KW - Kuwait 2
MK - Macedonia 2
PE - Perù 2
QA - Qatar 2
TZ - Tanzania 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CU - Cuba 1
CY - Cipro 1
GH - Ghana 1
HN - Honduras 1
IQ - Iraq 1
LK - Sri Lanka 1
PA - Panama 1
PR - Porto Rico 1
TN - Tunisia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 17.182
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.005
Beijing 618
Shanghai 487
Houston 417
Chandler 368
Fairfield 353
Redwood City 297
Guangzhou 243
Torino 240
Wilmington 199
Ashburn 197
Dublin 194
Woodbridge 193
Tokyo 191
Seattle 184
Cambridge 180
Hangzhou 174
Nanjing 149
Dearborn 137
New York 121
Milan 112
Singapore 89
Rome 85
Pisa 84
Wuhan 84
Taipei 80
Villeurbanne 77
Nyköping 75
Medford 69
London 68
Zhengzhou 64
Chengdu 56
Duncan 55
Boston 54
San Diego 54
Turin 54
Jacksonville 50
Princeton 49
Boardman 48
Barcelona 47
Seoul 47
Tianjin 46
Los Angeles 44
Paris 42
Rochester 42
Shenyang 42
Madrid 41
Ottawa 41
Buffalo 40
Fremont 40
Warsaw 40
Chicago 38
Chongqing 38
Munich 38
Norwalk 37
Changsha 36
Berlin 34
Jinan 34
Lappeenranta 31
Istanbul 30
Xian 29
Amsterdam 28
Brussels 28
Central District 27
Helsinki 26
Heidelberg 25
Melbourne 25
Nanchang 25
Philadelphia 25
Phoenix 25
Atlanta 24
Southend 24
Toronto 24
Vienna 24
Baltimore 23
Central 23
Shenzhen 23
Grafing 22
Hefei 22
Kunming 22
Mainz 22
San Francisco 22
Washington 22
Hong Kong 21
Pune 21
Bangkok 20
Bologna 20
Harbin 20
Moscow 20
Oslo 20
Redmond 20
San Mateo 20
Utrecht 20
Aioicho 19
Dallas 19
Dong Ket 19
Nutley 19
Fuzhou 18
Ludwigshafen 18
Mumbai 18
Totale 8.974
Salva come PNG Salva come JPEG
Nome #
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial 4.986
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth 1.760
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations 1.126
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer 1.048
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies 788
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor 690
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer 561
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology 547
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer 474
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer 427
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients 363
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition 358
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer 294
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer 280
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 267
How liquid biopsies can change clinical practice in oncology 233
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor 228
Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients 219
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer 208
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer 192
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer 181
Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. 180
Minimal residual disease in breast cancer: in blood veritas. 163
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer 158
Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer 148
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers 146
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer 144
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma 143
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer 140
Integrating liquid biopsies into the management of cancer 112
TAS-120 overcomes resistance to atp-competitive FGFR inhibitors in patients with FGFR2 fusion–positive intrahepatic cholangiocarcinoma 109
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer 108
The first-in-class anti-EGFR antibody mixture Sym004 overcomes cetuximab resistance mediated by EGFR extracellular domain mutations in colorectal cancer 108
Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers 90
Molecular heterogeneity and receptor coamplification drive resistance to targeted therapy in MET-Amplified esophagogastric cancer 86
Liquid biopsies to evaluate early therapeutic response in colorectal cancer 84
Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours 76
Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer 75
Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells 63
Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know 50
Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients 43
Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer 39
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. 32
Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer 27
Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers 19
Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patients’ avatars 6
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 5
Abstract C94: Heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer are sensitive to concomitant inhibition of EGFR and MEK 4
Abstract B33: The oligoclonal antibody MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations 4
Abstract 2149: The anti-EGFR antibody mixture Sym004 overcomes acquired resistance to cetuximab in colorectal cancer 3
Abstract B110: Heterogeneous genetic alterations emerge during acquired resistance to anti-EGFR therapy in colorectal cancer 3
Abstract 3588: Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer 2
Totale 17.600
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.428
article - articoli 0
book - libri 0
conference - conferenze 461
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.889
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.413 0 176 200 272 196 330 194 194 253 265 211 122
2020/20212.810 140 146 174 210 251 221 256 186 293 303 220 410
2021/20222.993 382 377 322 442 168 148 184 188 189 140 251 202
2022/20232.064 167 192 119 202 158 271 155 154 207 124 173 142
2023/20242.203 187 213 182 179 193 189 180 205 76 218 182 199
2024/2025160 158 2 0 0 0 0 0 0 0 0 0 0
Totale 17.600